Genetically encoding multiple functionalities into extracellular vesicles for the targeted delivery of biologics to T cells.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38012307.
- Also identified by DOI 10.1038/s41551-023-01142-x and PMC identifier 11088532.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The genetic modification of T cells has advanced cellular immunotherapies, yet the delivery of biologics specifically to T cells remains challenging. Here we report a suite of methods for the genetic engineering of cells to produce extracellular vesicles (EVs)-which naturally encapsulate and transfer proteins and nucleic acids between cells-for the targeted delivery of biologics to T cells without the need for chemical modifications. Specifically, the engineered cells secreted EVs that actively loaded protein cargo via a protein tag and that displayed high-affinity T-cell-targeting domains and fusogenic glycoproteins. We validated the methods by engineering EVs that delivered Cas9-single-guide-RNA complexes to ablate the gene encoding the C-X-C chemokine co-receptor type 4 in primary human CD4<sup>+</sup> T cells. The strategy is amenable to the targeted delivery of biologics to other cell types.
Medical subject headings
- Extracellular Vesicles
- Biological Products